Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

The Academy of Oncology Nurse & Patient Navigators and Gilead Sciences Partner to Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation…

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC)

Merck's KEYTRUDA Combo Cuts Risk By 35% In First-Line PD-L1+ Metastatic TNBC, Phase 3 Study Confirms

(RTTNews) - Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Posi

Gilead's Trodelvy, With Keytruda, Cuts Breast Cancer Risk by 35% in Trial

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.

Breast cancer risk cut by 35% in new clinical trial

Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.